Physician profile
James M Maisel
NPI 1720009525
$25,288.23
in general payments reported to CMS, 2019-2025
20 companies · $928 in 2025
The $928 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $21.50 · 2021: $134 · 2022: $368 · 2023: $772 · 2024: $3,823 · 2025: $928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,142 · Consulting Fee: $2,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,141.72 |
| Consulting Fee | $2,382.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $13,270.30 | 2019-2025 | Eylea Hd, Eylea |
| Allergan, INC. | $6,226.50 | 2019-2021 | |
| Astellas Pharma US INC | $2,799.77 | 2024-2025 | Izervay |
| Genentech USA, INC. | $664.15 | 2019-2025 | Vabysmo |
| Abbvie INC. | $522.80 | 2022-2024 | |
| Apellis Pharmaceuticals, INC. | $282.85 | 2023-2024 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $246.02 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $232.30 | 2019-2025 | Idosetr |
| Genentech, INC. | $125.01 | 2024 | Susvimo |
| Bausch & Lomb Americas INC. | $125.00 | 2024 | Miebo, Xiidra |
| Recordati_rare_diseases_inc. | $122.19 | 2024 | Cystadrops |
| Sun Pharmaceutical Industries INC. | $122.11 | 2023 | Cequa |
| Mallinckrodt Enterprises LLC | $119.34 | 2019 | |
| Kala Pharmaceuticals, INC. | $119.32 | 2019 | |
| Coherus Oncology, INC. | $92.44 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $74.90 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $71.29 | 2021 | |
| Mallinckrodt Hospital Products INC. | $26.89 | 2021 | |
| Amgen INC. | $24.64 | 2025 | Tepezza |
| Carl Zeiss Meditec USA, INC. | $20.41 | 2025 | Clarus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Maisel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.